HAVEN 2 Updated Analysis: Multicentre, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Paediatric Patients with Haemophilia A with Inhibitors

被引：0
|
作者：
Young, G. [1 ]
Sidonio, R. F. [2 ,3 ]
Liesner, R. [4 ]
Oldenburg, J. [5 ]
Chang, T. [6 ]
Uguen, M. [7 ]
Dhalluin, C. [7 ]
Schmitt, C. [7 ]
Levy, G. G. [6 ]
Shima, M. [8 ]
Mahlangu, J. [9 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Great Ormond St Hosp Sick Children, London, England
[5] Univ Klinikum Bonn, Bonn, Germany
[6] Genentech Inc, San Francisco, CA USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Nara Med Univ Hosp, Kashihara, Nara, Japan
[9] Univ Witwatersrand, Johannesburg, South Africa
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
emicizumab; haemophilia A; inhibitors; paediatric;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-OR-0
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
    Burns, A.
    Gauthier, S.
    Perdomo, C.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2007, 22 (08) : 806 - 812
  • [32] Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study
    Wang, Zhichao
    Zhang, Xin
    Li, Chunyan
    Liu, Yangbo
    Ge, Xiaoyun
    Zhao, Jiajia
    Yuan, Xiaojun
    Li, Qingfeng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (03):
  • [33] Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)
    Duffin, K. Callis
    Bagel, J.
    Bukhalo, M.
    Clement, I. J.
    Choi, S. L.
    Zhao, F.
    Gill, A.
    Pangallo, B.
    Shuler, C.
    Mallbris, L.
    Jackson, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 107 - 113
  • [34] Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher riskmyelodysplastic syndromes: Results from amulticenter, single-arm, open-label phase 2 study
    Du, Xin
    Lai, Yue-Yun
    Xiao, Zhijian
    Liu, Ting
    Hu, Yu
    Sun, Aining
    Li, Xiao
    Shen, Zhi-Xiang
    Jin, Jie
    Yu, Li
    Laille, Eric
    Dong, Qian
    Songer, Stephen
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (03) : 270 - 278
  • [35] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Tegoprubart (AT-1501) in Patients Undergoing Kidney Transplant
    Tchervenkov, Jean
    Coates, Patrick T.
    Kadatz, Matthew J.
    Bornstein, Jeffrey D.
    Gill, John S.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 967 - 967
  • [37] Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome
    Liu, Jialu
    Shen, Qian
    Xie, Li
    Wang, Jiyang
    Li, Yaxuan
    Chen, Jing
    Fang, Xiaoyan
    Tang, Xiaoshan
    Qian, Biyun
    Xu, Hong
    BMJ OPEN, 2022, 12 (10):
  • [38] A phase IB/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer.
    Del Priore, Giuseppe
    Hoffman, Steve
    Nixon, Daniel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Safety and Efficacy of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis
    Hyarns, Jeffrey S.
    Damaraju, Lakshmi
    Blank, Marion
    Johanns, Jewel
    Guzzo, Cynthia
    Winter, Harland S.
    Kugathasan, Sabra
    Cohen, Stanley A.
    Markowitz, James
    Veereman, Gigi
    Crandall, Wallace
    Baldassano, Robert
    Griffiths, Anne M.
    GASTROENTEROLOGY, 2011, 140 (05) : S124 - S125
  • [40] Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial
    Takeyama, Masahiro
    Ozu, Naoki
    Kasama, Shu
    Kasahara, Masato
    Matsumoto, Masanori
    Shima, Midori
    Nogami, Keiji
    BMJ OPEN, 2023, 13 (07):
12345